{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:05:52Z","timestamp":1793066752550,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Evidence regarding the influence of vedolizumab (VDZ) on extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) is limited. Our aim was to analyze the effectiveness of VDZ in preexisting EIMs and the occurrence of de novo EIMs during VDZ therapy for IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational, multicenter, retrospective cohort study included patients from the Spanish ENEIDA registry. All EIMs were assessed at baseline, and clinical response and worsening of IBD and EIMs were evaluated at 3 and 12\u2009months after VDZ initiation, according to the physician\u2019s assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We retrospectively identified 551 patients with IBD treated with VDZ. At baseline, 133 patients (24.1%) had preexisting EIMs, with 77 having active EIMs. At 3\u2009months, 29.9% of these patients showed clinical improvement, 16.9% experienced worsening, and 53.2% remained unchanged. Clinical response of IBD at 3\u2009months was the only factor associated with EIM improvement (OR\u20093.72; 95% CI 1.08-12.83). Among 56 patients with inactive EIMs at baseline, 13.5% experienced worsening after 12\u2009months. During follow-up, 25 patients (4.5%) developed 27 de novo EIMs. The presence of 2 preexisting EIMs was the only factor associated with de novo EIM onset (OR 16.2; 95% CI 4.3-60.9). Worsening of preexisting EIMs or de novo EIMs led to VDZ discontinuation in 15 patients (5.8% of all patients who discontinued VDZ and 2.7% of the entire cohort).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VDZ achieved clinical response of active EIMs in nearly one-third of patients after 3 months. Although infrequent, VDZ may exacerbate inactive EIMs and induce de novo EIMs during therapy, potentially leading to treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag024","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:30Z","timestamp":1774543050000},"source":"Crossref","is-referenced-by-count":1,"title":["Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-0254","authenticated-orcid":false,"given":"Pablo","family":"P\u00e9rez-Galindo","sequence":"first","affiliation":[{"name":"Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigaci\u00f3n Sanitaria Galicia Sur (IISGS) , Pontevedra,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-IP), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carrillo-Palau","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias , Tenerife,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bertoletti","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez-Viv\u00f3","sequence":"additional","affiliation":[{"name":"Hospital del Mar , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Pajares","sequence":"additional","affiliation":[{"name":"Hospital Universitario Infanta Sof\u00eda , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Merino","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Cruces , Barakaldo,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan \u00c1ngel","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Casta\u00f1o","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias , Oviedo,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-IP), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Calvo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-1477","authenticated-orcid":false,"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Santiago de Compostela , Santiago de Compostela,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufo Humberto","family":"Lorente","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Ciudad Real , Ciudad Real,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Algaba","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Fuenlabrada , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Madero-Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Dr. Balmis, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL) , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Vela","sequence":"additional","affiliation":[{"name":"Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saioa","family":"de la Maza","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Basurto , Bilbao,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordina","family":"Lla\u00f3","sequence":"additional","affiliation":[{"name":"Althaia, Xarxa Assistencial Universit\u00e0ria , Manresa,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Vega","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de Ourense , Ourense,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Utrilla","sequence":"additional","affiliation":[{"name":"Hospital General San Jorge , Huesca,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Almela","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Castell\u00f3n , Castell\u00f3n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-7196","authenticated-orcid":false,"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Aut\u00f2noma de Barcelona. Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carpio","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigaci\u00f3n Sanitaria Galicia Sur (IISGS) , Pontevedra,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ENEIDA Registry of GETECCU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026032612372864000_jjag024-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032612372864000_jjag024-B2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","article-title":"Biologics for extraintestinal manifestations of IBD","volume":"15","author":"Vavricka","year":"2014","journal-title":"Curr Drug Targets"},{"key":"2026032612372864000_jjag024-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032612372864000_jjag024-B4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"2026032612372864000_jjag024-B5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"2026032612372864000_jjag024-B6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026032612372864000_jjag024-B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026032612372864000_jjag024-B8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"Van Der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026032612372864000_jjag024-B9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032612372864000_jjag024-B10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032612372864000_jjag024-B11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2026032612372864000_jjag024-B12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00054725-199805000-00026","article-title":"Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD","volume":"4","author":"Salmi","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B13","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.166.7.4650","article-title":"Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules","volume":"166","author":"Salmi","year":"2001","journal-title":"J Immunol"},{"key":"2026032612372864000_jjag024-B14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.gastrohep.2020.05.007","article-title":"The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions","volume":"43","author":"Zabana","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"2026032612372864000_jjag024-B15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026032612372864000_jjag024-B16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032612372864000_jjag024-B17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/ibd\/izad075","article-title":"Impact of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: results from a descriptive, retrospective, real-world study","volume":"29","author":"Kopylov","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.dld.2018.02.013","article-title":"The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases","volume":"50","author":"Macaluso","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2026032612372864000_jjag024-B19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032612372864000_jjag024-B20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032612372864000_jjag024-B21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032612372864000_jjag024-B22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2022.09.009","article-title":"Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study","volume":"55","author":"Livne-Margolin","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026032612372864000_jjag024-B23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026032612372864000_jjag024-B24","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentre cohort study","volume":"16","author":"De Galan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032612372864000_jjag024-B27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: a multicenter study","volume":"27","author":"Ramos","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B28","doi-asserted-by":"crossref","first-page":"933357","DOI":"10.3389\/fmed.2022.933357","article-title":"The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study","volume":"9","author":"Ferretti","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026032612372864000_jjag024-B29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/ecco-jcc\/jjaa078","article-title":"Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series","volume":"14","author":"Phillips","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026032612372864000_jjag024-B30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026032612372864000_jjag024-B31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026032612372864000_jjag024-B32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","article-title":"Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits","volume":"10","author":"Taleban","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026032612372864000_jjag024-B33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag024\/67554522\/jjag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag024\/67554522\/jjag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:34Z","timestamp":1774543054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag024\/8541952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag024","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"jjag024"}}